The chairman of the panel, William Busse, is a doctor and professor at the University of Wisconsin School of Medicine and Public Health, whose financial relationships with asthma drug makers include years of work as a paid adviser, speaker and consultant.
At the time the guidelines were issued, Busse disclosed that he worked as a speaker and adviser for GlaxoSmithKline and several other drug companies, though specific amounts of money were not listed.